FMR LLC Discloses 13.265% Stake in Cytokinetics (CYTK)
Ticker: CYTK · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | SC 13G/A |
| Filed Date | Feb 9, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**FMR LLC still owns 13.265% of CYTK, a strong institutional endorsement.**
AI Summary
FMR LLC, a major investment firm, has updated its ownership stake in Cytokinetics Inc. (CYTK) through an SC 13G/A filing on February 9, 2024. FMR LLC and its principal owner, Abigail P. Johnson, now beneficially own 13,007,783 shares of Cytokinetics' common stock, representing 13.265% of the company. This filing indicates a significant, passive investment by FMR LLC, signaling their continued confidence in Cytokinetics' future, which could be a positive signal for current and prospective investors.
Why It Matters
This filing shows that a large, influential institutional investor, FMR LLC, maintains a substantial stake in Cytokinetics, which can be interpreted as a vote of confidence in the company's long-term prospects.
Risk Assessment
Risk Level: low — This filing is an update to a passive investment, indicating no immediate change in strategy or significant new risks for the company.
Analyst Insight
A smart investor would view FMR LLC's continued substantial ownership as a positive signal, suggesting institutional confidence in Cytokinetics' long-term value, and might consider further research into the company's fundamentals.
Key Numbers
- 13,007,783 — Shares Beneficially Owned (Total common stock shares of Cytokinetics Inc. owned by FMR LLC and Abigail P. Johnson)
- 13.265% — Percent of Class (The percentage of Cytokinetics Inc.'s common stock class beneficially owned by FMR LLC and Abigail P. Johnson)
- 0000315066-24-001078 — Accession Number (Unique identifier for this specific SEC filing)
- 20240209 — Filed As Of Date (The date this SC 13G/A filing was officially submitted to the SEC)
Key Players & Entities
- FMR LLC (company) — the reporting person and parent holding company
- Cytokinetics Inc. (company) — the issuer of the common stock
- Abigail P. Johnson (person) — principal owner of FMR LLC, also reporting beneficial ownership
- Boston, Massachusetts (company) — business address of FMR LLC
- South San Francisco, CA (company) — principal executive offices of Cytokinetics Inc.
Forward-Looking Statements
- FMR LLC will maintain a significant, passive stake in Cytokinetics Inc. for the foreseeable future. (FMR LLC) — high confidence, target: 2025-02-09
FAQ
What is the primary purpose of this SC 13G/A filing by FMR LLC regarding Cytokinetics Inc.?
This SC 13G/A filing is an amendment (Amendment No.3) to a Schedule 13G, indicating an update to FMR LLC's beneficial ownership of Cytokinetics Inc. common stock, filed pursuant to Rule 13d-1(b).
How many shares of Cytokinetics Inc. common stock does FMR LLC beneficially own, and what percentage of the class does this represent?
FMR LLC beneficially owns 13,007,783 shares of Cytokinetics Inc. common stock, which represents 13.265% of the class, as stated in Item 4(a) and 4(b) of the filing.
Who is Abigail P. Johnson, and what is her reported ownership in Cytokinetics Inc. according to this filing?
Abigail P. Johnson is a reporting person associated with FMR LLC, and she also beneficially owns 13,007,783 shares, representing 13.265% of Cytokinetics Inc. common stock, as detailed in her individual reporting person section.
What is the CUSIP number for Cytokinetics Inc. common stock mentioned in the filing?
The CUSIP number for Cytokinetics Inc. common stock is 23282W605, as specified in Item 2(e) of the filing.
Where are the principal executive offices of Cytokinetics Inc. located, according to this filing?
The principal executive offices of Cytokinetics Inc. are located at 350 OYSTER POINT BOULEVARD, South San Francisco, CA 94080 USA, as stated in Item 1(b) of the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding CYTOKINETICS INC (CYTK).